Hypothesis

Tissue-specific TET2 activity, rather than a fixed OSK expression timer, determines the safe window for cyclic partial reprogramming. We propose that OSK induces a transient surge in TET2‑mediated DNA demethylation that rejuvenates epigenetic age but, if prolonged beyond a tissue‑dependent threshold, triggers ectopic activation of pluripotency networks and loss of somatic identity. Real‑time monitoring of ribosomal DNA (rDNA) methylation, which tracks OSK‑induced demethylation within 4‑7 days, can be coupled to a tissue‑restricted degron‑TET2 sensor that reports the instantaneous demethylation rate. When the sensor crosses a pre‑set threshold, a feedback loop triggers expression of a dominant‑negative TET2 or a small‑molecule TET2 inhibitor, terminating OSK activity before dedifferentiation occurs.

Mechanistic Reasoning

OSK‑driven TET1/2 activation demethylates CpG islands at enhancers of lineage‑specific genes, restoring youthful methylation patterns [1]. However, single‑cell ATAC‑seq shows that tissues differ in baseline chromatin accessibility at these enhancers [2]. In highly accessible tissues (e.g., liver, kidney) a modest TET2 increase suffices for demethylation, whereas in less accessible tissues (e.g., pancreas, intestine) higher TET2 activity is required, raising the risk of overshooting into pluripotency‑associated loci. Thus, the same OSK dose yields different effective demethylation rates across organs, explaining the observed tissue‑specific outcomes [2]. By linking the demethylation rate to a degradable TET2‑sensor (e.g., a TET2‑binding domain fused to a degron whose stability reflects local 5‑hmC levels), the system self‑adjusts: high demethylation accelerates sensor degradation, reducing TET2 activity and preventing excess plasticity.

Testable Predictions

1. In vivo delivery of AAV‑OSK together with a liver‑specific TET2‑sensor‑degron construct will extend the safe cyclic interval from 2 days ON/5 days OFF to 3 days ON/4 days OFF without increasing ectopic OCT4+ cells, whereas the same sensor in pancreas will shorten the safe interval to 1 day ON/6 days OFF.
2. Pharmacological inhibition of TET2 (e.g., with Bobcat339) administered after the sensor‑detected threshold will block further demethylation, preserve somatic identity markers (e.g., ALB for hepatocytes, KRT8 for epithelial cells), and abolish any teratoma formation, while still permitting the epigenetic age reversal achieved before inhibition.
3. Measuring circulating cell‑free DNA (cfDNA) rDNA methylation levels will correlate tightly with tissue‑specific sensor readouts, providing a non‑invasive biomarker for adjusting OSK dosing in real time.

Experimental Design

• Generate three AAV vectors: (1) OSK under a doxycycline‑inducible promoter, (2) a tissue‑specific (Albumin‑ or Pdx1‑promoter) TET2‑sensor‑degron‑GFP construct, (3) a constitutive mCherry control.
• Treat aged mice with doxycycline cycles; monitor GFP fluorescence (sensor stability) and cfDNA rDNA methylation every 12 h.
• Define the threshold GFP level at which OCT4+ ectopic cells appear (immunostaining).
• Adjust doxycycline exposure to keep GFP below threshold; compare epigenetic age (Horvath clock), functional assays (glucose tolerance, ALT/AST), and tumorigenesis over 6 months.
• Repeat with TET2 inhibitor administered upon threshold crossing.

If the hypothesis is correct, adaptive termination guided by TET2 activity will widen the therapeutic window of OSK reprogramming, reduce tissue‑specific adverse effects, and provide a translatable closed‑loop platform for human trials.

Falsifiability

Observing no difference in safe cycling intervals between sensor‑equipped and control OSK groups, or finding that TET2 inhibition after threshold does not prevent ectopic pluripotency marker emergence, would refute the proposed mechanism.